Publications by authors named "F Tricta"
Importance: Interventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide. Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target.
Objective: To investigate whether the brain-permeable iron chelator deferiprone slows cognitive decline in people with AD.
Patients treated with deferiprone for transfusional iron overload may experience idiosyncratic drug-induced neutropenia (IDIN) that may increase risk of infection. This analysis examined the rates of severe IDIN and risk of serious infections at different absolute neutrophil count (ANC) levels during deferiprone treatment. Events of severe IDIN (ANC <0.
View Article and Find Full Text PDFPatients with sickle cell disease (SCD) and other anemias who receive blood transfusions are at risk of organ damage due to transfusional iron overload. Deferiprone is an iron chelator with a well-established safety and efficacy profile that is indicated for the treatment of transfusional iron overload. Here, we report safety data from the large-scale, retrospective Ferriprox® Total Care Registry, which involved all patients with SCD taking deferiprone following the 2011 approval of deferiprone in the United States through August 2020.
View Article and Find Full Text PDFArticle Synopsis
- Kids with sickle cell disease often need help to get rid of extra iron from blood transfusions, and there are two treatments called deferiprone and deferoxamine that help with this.
- A study looked at 142 kids under 18 years old who were being treated with either deferiprone or deferoxamine, showing that both treatments worked similarly in reducing iron levels after 12 months.
- Deferiprone is a pill that might be easier for kids to take, and it wasn't found to have any new safety problems compared to deferoxamine.
Extramedullary haematopoiesis in patients with thalassemia: a cross-sectional description of its prevalence, clinical features and survival.
Hematol Transfus Cell Ther
November 2024
Introduction: Despite knowledge advances on extramedullary haematopoiesis (EMH) in thalassemic patients, the real picture remains an open issue.
Objectives: To assess EMH prevalence in patients with thalassemia major (TM) and intermedia (TI), to describe magnetic resonance imaging (MRI) findings and to explore clinical risk factors.
Methods: In this cross-sectional study, images and clinical records of 184 consecutive patients with thalassemia who underwent T2* MRI between 2004 and 2011 were reviewed.